The peptide Epitalon (AEDG; Ala-Glu-Asp-Gly) increased telomerase activity and telomere length in cultured human cells, including in more recent experiments from 2025, but currently there is no strong clinical evidence showing that Epitalon lengthens telomeres in living humans, reverses biological ageing or extends human life. [1–4]
The telomere hypothesis is one of the best-known aspects of research into Epitalon, but also one of the easiest to over-interpret. The strongest evidence comes from in vitro studies on human cells, rather than from individuals receiving Epitalon in controlled clinical trials. Studies have shown changes in hTERT expression, telomerase activity, telomere length, replicative capacity and — in cancer cells — alternative telomere lengthening (ALT). These results confirm biological activity but do not prove the efficacy of anti-ageing therapy.
Does Epitalon Activate Telomerase?
Yes. Epitalon activated telomerase in cultured human somatic cells. Both earlier experiments on fibroblasts and a 2025 study on human cells showed increased telomerase-associated activity. However, these are in vitro data and do not prove systemic telomerase activation or a clinical anti-ageing effect in living humans. [2–4]
Telomerase is an enzyme complex involved in maintaining chromosome ends, known as telomeres. Most differentiated human somatic cells have relatively low telomerase activity, whereas stem cells, germ cells and many cancer cells utilise telomerase or other mechanisms to maintain telomere length.
One of the fundamental studies on Epitalon was published in 2003. In an in vitro experiment on human foetal fibroblasts, Khavinson, Bondarev and Butyugov demonstrated that exposure to Epithalon induced the expression of the catalytic component of telomerase, led to detectable telomerase enzymatic activity, and was associated with telomere elongation. [2]
Another study of human fibroblast cultures evaluated whether these molecular changes affected the replicative capacity of the cells. The researchers noted that foetal fibroblasts treated with Epithalon maintained longer telomeres and continued to divide past the point at which control cells stopped proliferating. [3]
A newer study by Al-Dulaimi and colleagues analysed the effects of Epitalon on several normal and cancer human cell lines. The 2025 in vitro study found a significant increase in telomerase activity in normal fibroblasts and epithelial cells, which was accompanied by an increase in hTERT expression and telomere length. [4]
More recent results strengthen the evidence that Epitalon can affect telomerase biology in laboratory conditions. However, they do not prove that administered Epitalon activates telomerase in various human tissues in vivo.
A broader discussion of related pathways can be found in the internal article „Mechanism of Action of Epitalon: How This Peptide Works”.
Can Epitalon Lengthen Telomeres?
Epitalon lengthened telomeres in cultured normal human fibroblasts and epithelial cells, as well as in experimental tumour cell lines. To date, however, no well-controlled clinical trial in humans has been conducted to demonstrate that Epitalon increases telomere length in living individuals. [2–4]
The distinction between telomere elongation in cell cultures and telomere elongation in humans is crucial.
A 2003 study on human cells reported telomere elongation following the application of Epithalon in telomerase-negative foetal fibroblasts. [2] In a subsequent study from 2004, ageing fibroblasts treated with the peptide achieved telomere lengths comparable to those observed in earlier passages. [3]
A 2025 study provides more detailed data. The researchers exposed normal human fibroblasts, normal human mammary epithelial cells, and breast cancer cell lines 21NT and BT474 to Epitalon. In the tested models, telomere length increased in a dose- and exposure-time-dependent manner. [4]
However, the mechanism differed depending on the cell type.
In normal fibroblasts and epithelial cells, telomere lengthening occurred alongside an increase in hTERT mRNA and telomerase activity. In cancer cell lines, telomeres also lengthened, but the researchers found that alternative telomere lengthening, namely ALT, played a significant role. [4]
This difference is scientifically significant. It shows that the statement „Epitalon lengthens telomeres” does not describe a single universal mechanism acting identically in all cells.
This also means that telomere lengthening should not automatically be interpreted as beneficial. Telomere maintenance mechanisms play a role in both normal cell renewal and the ability of many cancer cells to continue dividing.
What do cellular studies on Epitalon and telomerase show?
Studies on human cells show that Epitalon may increase hTERT expression, telomerase activity, telomere length and replicative capacity under specific laboratory conditions. Studies on cancer cells, however, show that telomere lengthening may also occur via ALT, and not exclusively via telomerase. [2–4]
The main studies can be separated according to what was actually evaluated.
| Study | Experimental model | Main telomere result | Level of evidence |
|---|---|---|---|
| Khavinson, Bondarev & Butyugov, 2003 | Human foetal fibroblasts | Expression of the catalytic subunit of telomerase, telomerase activity and telomere lengthening | In vitro studies on human cells [2] |
| Khavinson et al., 2004 | Ageing human foetal fibroblasts | Longer telomeres and additional cell divisions | In vitro studies on human cells [3] |
| Al-Dulaimi et al., 2025 | Normal fibroblasts and mammary gland epithelial cells | Increase in hTERT, telomerase activity and telomere length | In vitro studies on human cells [4] |
| Al-Dulaimi et al., 2025 | Breast cancer cells 21NT and BT474 | Telomere lengthening with a significant contribution from ALT | In vitro studies on cancer cells [4] |
Older studies on fibroblasts are particularly relevant in the context of the so-called Hayflick limit.
Normal human somatic cells do not divide indefinitely. In culture, many of them enter a state of replicative senescence after a certain number of divisions. Telomere shortening is one of the factors contributing to this phenomenon, although it is not the sole determinant of cellular ageing.
In a 2004 study, foetal lung fibroblasts were found to lose their proliferative capacity around the 34th passage. Following exposure to Epitalon, the cells treated with the peptide developed longer telomeres and underwent about 10 additional passages, reaching at least passage 44. [3]
The authors described this as exceeding the Hayflick limit. A more cautious modern interpretation is that Epithalon prolonged the replicative lifespan of this specific population of cultured fibroblasts. This does not mean that human biological life can be extended by a similar value or through the same mechanism.
Are there human studies showing telomere lengthening?
There is evidence from studies on human cells indicating telomere elongation following the use of Epitalon, but convincing in vivo clinical data showing that telomeres become longer in individuals receiving Epitalon are still lacking. Cultured human cells should therefore not be presented as evidence of „telomere rejuvenation” in humans. [2–4]
This distinction is often blurred because scientific publications may use terms such as „human somatic cells”.
In this context, „human” refers to the origin of the cells, rather than to a clinical study conducted on living participants.
Early telomerase studies used human foetal fibroblasts cultured in laboratory conditions. [2,3] A 2025 study also used established human fibroblast, epithelial cell and breast cancer cell lines. [4]
These are valuable models because they allow researchers to directly analyse telomere biology under controlled conditions. However, they still differ from a living human organism in many respects, including metabolism, substance distribution, immune response, peptide degradation, exposure of individual tissues, hormonal regulation, and multi-organ interactions.
Clinical confirmation of telomere lengthening would require giving humans a strictly defined intervention as part of a controlled protocol, validated measurements of telomere length before and after treatment, and appropriate comparison groups.
The research on Epitalon presented in this article does not provide that level of evidence.
Therefore, statements such as „Epitalon lengthens human telomeres” are too broad unless it is clearly stated that they refer to cultured human cells.
How does hTERT relate to telomerase activity?
hTERT is the protein catalytic component of telomerase, therefore increasing hTERT expression can support telomerase activity. However, the hTERT mRNA level does not necessarily predict functional enzyme activity, which was demonstrated particularly clearly by the 2025 Epitalon study on cancer cell lines. [4]
Human telomerase contains several components, but human telomerase reverse transcriptase, or hTERT, provides the catalytic activity needed to add repeating telomeric DNA sequences.
Therefore, hTERT expression is an important molecular marker in telomerase research.
A 2025 study measured several related but distinct parameters:
- hTERT mRNA expression indicates hTERT gene transcription,
- telomerase enzymatic activity shows whether the functional enzyme is actively synthesising telomeric DNA,
- telomere length determines the length of telomeric chromosome fragments,
- ALT activity measures an alternative mechanism for telomere maintenance that does not rely primarily on classical telomerase activity.
In the experiment, Epitalon increased hTERT expression in both normal and cancer cells. [4]
In normal cells, this was accompanied by a significant increase in the functional activity of telomerase. The researchers noted an approximately fourfold increase in IBR.3 fibroblasts and an approximately 26-fold increase in normal human mammary epithelial cells compared to untreated control cells under the conditions of this study. [4]
Cancer cells behaved differently. Despite an increase in hTERT mRNA, telomerase activity did not increase proportionally. Instead, the researchers observed a significant increase in ALT activity, suggesting that telomere elongation in these cancer cells occurred via a different mechanism. [4]
This is an important example showing why molecular biomarkers should not be interpreted in isolation from other data. Increased hTERT transcription does not automatically mean a proportional increase in active telomerase.
Could telomerase activation theoretically be associated with a risk?
The potential risk is biologically plausible, as telomere maintenance mechanisms help many cancer cells to continue dividing. However, current research into Epitalon does not prove that the peptide causes cancer in humans. The most reasonable conclusion is that the effects on telomerase and ALT require further safety studies and should not automatically be regarded as either beneficial or harmful. [1,4]
Telomere shortening represents one of several barriers limiting the unlimited replication of cells. When very short telomeres trigger a DNA damage response, cells can enter a state of senescence or apoptosis.
Tumour biology complicates this relationship, as malignant cells often have to bypass this barrier.
Many cancers reactivate telomerase, whilst others utilise ALT to maintain telomeres and sustain proliferation. Therefore, the activation of telomere maintenance mechanisms is not automatically synonymous with anti-ageing effects.
The experiment conducted in 2025 is particularly significant. In both breast cancer cell lines, a significant lengthening of telomeres was observed following treatment with Epitalon. However, in contrast to normal cells, a significant proportion of this effect was associated with increased ALT activity. [4]
The study therefore raises the question of mechanistic safety, but does not provide a definitive answer to it.
It does not show that Epitalon initiates tumour development, causes cancer or clinically accelerates its progression.
On the other hand, older animal studies on Epitalon described a reduced tumour incidence or inhibition of their development in several experimental models, including HER-2/neu mammary tumours and chemically induced colorectal carcinogenesis. [5–7] Other animal models, however, showed no anti-tumour effect, as in the experiment with induced urinary bladder tumours. [8]
These seemingly contradictory results emphasise that cancer biology is strongly model-dependent. The results observed in rodents do not resolve the question of the safety of Epitalon's effect on telomere maintenance in humans.
The most reasonable interpretation is therefore that the effect of Epitalon on telomerase and ALT requires specific long-term studies, particularly before any firm conclusions can be drawn regarding safety or cancer prevention.
What the Evidence Does Not Support in the Context of Longevity
The effect of Epitalon on telomerase and telomeres does not prove that the peptide slows down human ageing, reverses biological age, prevents age-related diseases, increases healthspan, or extends human life. Telomere length is only one element of the biology of ageing, and the available evidence regarding Epitalon and telomeres is mainly cellular rather than clinical.
The following logical sequence is often presented on the internet:
Epitalon → telomerase → longer telomeres → younger cells → longer human lifespan.
Published evidence only supports part of this scheme.
The first stages have experimental confirmation in specific human cell cultures. Epitalon increased hTERT, activated telomerase and lengthened telomeres in normal fibroblast and epithelial cell models. [2–4]
The later stages have not been clinically confirmed.
Telomeres are linked to replicative cellular ageing, but biological ageing also involves mitochondrial dysfunction, epigenetic changes, DNA damage, impaired protein homeostasis, cellular senescence, altered intercellular communication, stem cell exhaustion, immune changes, metabolic disorders and many other interrelated processes.
Even in animal lifespan studies, the results concerning Epitalon are not consistent.
A 2003 mouse longevity experiment found no significant increase in the mean lifespan of female Swiss-derived SHR mice, although maximum lifespan and survival in the longest-lived animal group increased. [9]
Previous studies on Drosophila have shown an increase in lifespan of approximately 11–16% under specific experimental conditions. [10]
Other studies on rodents indicated that the effects depended on lighting conditions, sex, strain, and whether mean or maximum survival was analysed.
These studies indicate a preclinical signal associated with longevity. However, they do not allow it to be determined whether Epitalon extends human life.
An additional conceptual problem is that longer telomeres do not necessarily have to be beneficial. Senescence can limit the proliferation of damaged cells, whilst telomere maintenance mechanisms can help cancer cells survive. The biological goal cannot therefore simply be to „lengthen all telomeres”.
A scientifically more accurate conclusion is narrower: Epitalon is an experimentally active regulator of telomere maintenance pathways in cultured cells, but it is unknown whether this effect translates into a meaningful improvement in human longevity.
How Strong is the Overall Evidence Regarding Epitalon and Telomeres?
The evidence is strongest for the cellular effect and weakest for the impact on human longevity.
Studies on human cells conducted over a period of more than two decades have demonstrated effects related to telomerase or telomere length. A more recent study from 2025 provides detailed measurements of hTERT, telomerase activity, telomere length and ALT, making the molecular evidence more comprehensive than before. [2–4]
At the same time, there is still a large translation gap.
The presented evidence lacks robust randomised human trials demonstrating increased leukocyte telomere length, telomere lengthening in specific tissues, delayed clinical ageing, reduced age-related morbidity or increased survival following Epitalon administration.
The relationship can therefore be summarised as follows:
Does Epitalon Affect hTERT in Cultured Cells?
Yes. In a 2025 in vitro study on human cells, Epitalon increased hTERT mRNA expression in normal fibroblasts and epithelial cells, as well as in two breast cancer cell lines, although the subsequent telomerase response varied depending on the cell type. [4]
Does Epitalon Activate Telomerase in Cultured Normal Human Cells?
Yes. In vitro studies using normal human cells have demonstrated an increase in telomerase activity following exposure to Epitalon, in both earlier experiments on foetal fibroblasts and a 2025 study on normal fibroblasts and mammary epithelial cells. [2,4]
Can Epitalon Lengthen Telomeres in Cultured Human Cells?
Yes. Studies on human cell cultures have demonstrated telomere lengthening after the application of Epitalon in foetal fibroblasts, normal fibroblasts, normal epithelial cells, and certain lines of cells of neoplastic origin. However, these results do not confirm telomere lengthening in living humans. [2–4]
Can Epitalon Extend the Replicative Lifespan of Fibroblasts?
That is possible in vitro. In one study of human foetal fibroblast cultures, cells treated with Epitalon maintained longer telomeres and divided for about 10 additional passages compared to control cells. This indicates an extension of the replicative lifespan in this specific laboratory model. [3]
Does Epitalon Lengthen Telomeres in Living Humans?
This has not been established. The strongest published evidence comes from cultured human cells, rather than controlled clinical trials measuring telomere length before and after the administration of Epitalon in humans. [2–4]
Does Epitalon Systemically Reverse Cellular Ageing in Humans?
No such effect has been demonstrated. Although in vitro and preclinical studies describe changes regarding telomerase, telomeres, chromatin, oxidative stress pathways and other markers associated with ageing, there is no evidence that Epitalon reverses cellular ageing in the whole human body.
Does Telomerase Activation Guarantee Longevity?
No. Telomerase can support the maintenance of telomeres, but the ageing process is influenced by many other mechanisms, including mitochondrial dysfunction, DNA damage, epigenetic changes, cellular senescence, changes in the immune system, and metabolic regulation. Therefore, the activation of telomerase alone does not prove life extension.
Does Epitalon Extend Human Life?
There is no evidence that Epitalon extends human lifespan. Some animal studies have shown changes in maximum lifespan or survival in specific models, but these results cannot be directly extrapolated to humans and do not constitute clinical proof of life extension.
Is the effect of Epitalon on cancers fully understood?
No. This relationship remains uncertain. In a 2025 in vitro study, telomere elongation was observed in cancer cell lines via increased activity of the alternative telomere elongation pathway (ALT), whilst several older animal tumour models showed a reduction in certain parameters associated with tumour development. These results are model-specific and do not confirm either an anti-tumour effect or an increased risk of cancer in humans. [4]
This distinction between molecular and clinical evidence should remain a central element of any discussion about Epitalon as a „telomerase peptide” or a compound used „for telomeres”.
Limitations of Current Evidence
The main limitation is that the most important findings regarding telomeres come primarily from in vitro studies.
Cell cultures allow for precise measurements, but they do not reproduce the full pharmacokinetics and physiology of a living human. The concentration reaching a cultured fibroblast is directly controlled by researchers, whereas an administered peptide must survive degradation, enter the circulation, distribute into tissues, reach the target cells and remain biologically active.
Older telomerase studies were also relatively small laboratory experiments and came from the same broader research programme from which much of the early literature concerning Epitalon originates. The 2025 study adds important newer data from an independent research group, but it still remains a cellular study.
Another limitation is the fact that telomere length itself constitutes a surrogate biomarker rather than a direct clinical endpoint.
Finally, the discovery that Epitalon affected ALT in tumour-derived cells shows that telomere biology cannot be interpreted solely in terms of longevity. [4]
Future evidence would be much stronger if controlled human trials measured Epitalon pharmacokinetics, tissue exposure, telomerase activity, validated telomere parameters, clinical markers of ageing, adverse events and long-term cancer incidence.
Disclaimer
This article is for educational and scientific-informational purposes only and does not constitute medical advice, diagnosis, therapeutic recommendations, dosing guidance, or a recommendation for the use of Epitalon. Epitalon/Epithalon (AEDG; Ala-Glu-Asp-Gly) has not been approved by the FDA for telomere extension, anti-ageing applications, longevity, or any other uses discussed in this article. FDA records indicate that the previous orphan drug designation for retinitis pigmentosa was not approved for that indication, and the FDA has separately stated that it does not have sufficient safety information regarding compounded preparations containing Epitalon for the routes of administration analysed. In July 2026, the FDA was also reviewing active substances related to Epitalon in the context of pharmacy compounding, which is a separate issue from the approval of Epitalon as a medicinal product. The evidence concerning telomerase and telomeres discussed in this article is derived primarily from in vitro studies on human cells and does not confirm clinical efficacy, human lifespan extension, or long-term safety.
References
[1] Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly bioactive pineal tetrapeptide with promising properties. International Journal of Molecular Sciences, 26(6), 2691. https://doi.org/10.3390/ijms26062691
[2] Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592. https://doi.org/10.1023/A:1025493705728
[3] Khavinson, V. K., Bondarev, I. E., Butyugov, A. A., & Smirnova, T. D. (2004). Peptide promotes overcoming of the division limit in human somatic cell. Bulletin of Experimental Biology and Medicine, 137(5), 503–506. https://doi.org/10.1023/B:BEBM.0000038164.49947.8C
[4] Al-Dulaimi, S., Thomas, R., Matta, S., & Roberts, T. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology, 26(5), Article 178. https://doi.org/10.1007/s10522-025-10315-x
[5] Anisimov, V. N., Khavinson, V. K., Provinciali, M., Alimova, I. N., Baturin, D. A., Popovich, I. G., Zabezhinski, M. A., Imyanitov, E. N., Mancini, R., & Franceschi, C. (2002). Inhibitory effect of the peptide Epitalon on the development of spontaneous mammary tumours in HER-2/neu transgenic mice. International Journal of Cancer, 101(1), 7-10. https://doi.org/10.1002/ijc.10570
[6] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., & Zabezhinski, M. A. (2002). Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats. Cancer Letters, 183(1), 1–8. https://doi.org/10.1016/S0304-3835(02)00090-3
[7] Kossoy, G., Zandbank, J., Tendler, E., Anisimov, V., Khavinson, V., Popovich, I., Zabezhinski, M., Zusman, I., & Ben-Hur, H. (2003). Epitalon and colon carcinogenesis in rats: Proliferative activity and apoptosis in colon tumours and mucosa. International Journal of Molecular Medicine, 12(4), 473–477. https://pubmed.ncbi.nlm.nih.gov/12964022/
[8] Pliss, G. B., Mel’nikov, A. S., Malinin, V. V., & Khavinson, V. K. (2001). Effect of Vilon and Epithalone on induction and growth of induced bladder neoplasms in rats. Voprosy Onkologii, 47(5), 601–607. https://pubmed.ncbi.nlm.nih.gov/11785104/
[9] Anisimov, V. N., Khavinson, V. K., Popovich, I. G., Zabezhinski, M. A., Alimova, I. N., Rosenfeld, S. V., Zavarzina, N. Y., Semenchenko, A. V., & Yashin, A. I. (2003). Effect of Epitalon on biomarkers of ageing, life span and spontaneous tumour incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. https://doi.org/10.1023/A:1025114230714
[10] Khavinson, V. K., Izmaylov, D. M., Obukhova, L. K., & Malinin, V. V. (2000). Effect of Epitalon on the lifespan increase in Drosophila melanogaster. Mechanisms of Ageing and Development, 120(1–3), 141–149. https://doi.org/10.1016/S0047-6374(00)00217-7